StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.96+0.01 (+1.44%)

Close on Nov 17, 2026Market cap $26.64MP/E –Yield –

Inmune Bio total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Inmune Bio's total debt was $2.49M at Sep 30, 2024. For fiscal 2023 it was $9.92M, down 32.5% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2023Dec 31, 2023$9.92M-32.5%
FY2022Dec 31, 2022$14.70M+1987.6%
FY2021Dec 31, 2021$704.00K+340.0%
FY2020Dec 31, 2020$160.00K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024$2.49M+480.0%
Q2 FY2024Jun 30, 2024$4.98M+975.4%
Q1 FY2024Mar 31, 2024$7.46M-49.3%
Q4 FY2023Dec 31, 2023$9.92M+1534.4%
Q3 FY2023Sep 30, 2023$430.00K-33.3%
Q2 FY2023Jun 30, 2023$463.00K-32.3%
Q4 FY2022Dec 31, 2022$14.70M+1987.6%
Q3 FY2022Sep 30, 2022$607.00K-95.8%
Q2 FY2022Jun 30, 2022$645.00K+303.1%
Q1 FY2022Mar 31, 2022$684.00K–
Q4 FY2021Dec 31, 2021$704.00K–
Q2 FY2021Jun 30, 2021$14.35M–
Q4 FY2020Dec 31, 2020$160.00K–

More Inmune Bio figures

See a number that looks wrong?